238 related articles for article (PubMed ID: 34509954)
1. Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR.
de la Fouchardière C; Godbert Y; Dalban C; Illouz F; Wassermann J; Do Cao C; Bardet S; Zerdoud S; Chougnet CN; Zalzali M; Benisvy D; Niccoli P; Digue L; Lamartina L; Schwartz P; Borson Chazot F; Gautier J; Pérol D; Leboulleux S;
Eur J Cancer; 2021 Nov; 157():153-164. PubMed ID: 34509954
[TBL] [Abstract][Full Text] [Related]
2. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
3. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Bible KC; Suman VJ; Molina JR; Smallridge RC; Maples WJ; Menefee ME; Rubin J; Sideras K; Morris JC; McIver B; Burton JK; Webster KP; Bieber C; Traynor AM; Flynn PJ; Goh BC; Tang H; Ivy SP; Erlichman C; ; ;
Lancet Oncol; 2010 Oct; 11(10):962-72. PubMed ID: 20851682
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
[TBL] [Abstract][Full Text] [Related]
5. An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Bible KC; Menefee ME; Lin CJ; Millward MJ; Maples WJ; Goh BC; Karlin NJ; Kane MA; Adkins DR; Molina JR; Donehower RC; Lim WT; Flynn PJ; Richardson RL; Traynor AM; Rubin J; LoRusso PM; Smallridge RC; Burton JK; Suman VJ; Kumar A; Voss JS; Rumilla KM; Kipp BR; Chintakuntlawar AV; Harris P; Erlichman C
Thyroid; 2020 Sep; 30(9):1254-1262. PubMed ID: 32538690
[No Abstract] [Full Text] [Related]
6. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
7. A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine.
Chow LQ; Santana-Davila R; Pantel A; Roth M; Anderson LN; Failor A; Doot R; Mankoff D
PLoS One; 2017; 12(6):e0178325. PubMed ID: 28662033
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
Toulmonde M; Pulido M; Ray-Coquard I; Andre T; Isambert N; Chevreau C; Penel N; Bompas E; Saada E; Bertucci F; Lebbe C; Le Cesne A; Soulie P; Piperno-Neumann S; Sweet S; Cecchi F; Hembrough T; Bellera C; Kind M; Crombe A; Lucchesi C; Le Loarer F; Blay JY; Italiano A
Lancet Oncol; 2019 Sep; 20(9):1263-1272. PubMed ID: 31331699
[TBL] [Abstract][Full Text] [Related]
9. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
[TBL] [Abstract][Full Text] [Related]
11. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
Somaiah N; Van Tine BA; Wahlquist AE; Milhem MM; Hill EG; Garrett-Mayer E; Armeson KE; Schuetze SM; Meyer CF; Reuben DY; Elias AD; Read WL; Chawla SP; Kraft AS
Cancer; 2021 Mar; 127(6):894-904. PubMed ID: 33231866
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
[TBL] [Abstract][Full Text] [Related]
13. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
O'Brien ME; Gaafar R; Hasan B; Menis J; Cufer T; Popat S; Woll PJ; Surmont V; Georgoulias V; Montes A; Blackhall F; Hennig I; Schmid-Bindert G; Baas P;
Eur J Cancer; 2015 Aug; 51(12):1511-28. PubMed ID: 26074395
[TBL] [Abstract][Full Text] [Related]
14. Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.
Cirkel GA; Hamberg P; Sleijfer S; Loosveld OJL; Dercksen MW; Los M; Polee MB; van den Berkmortel F; Aarts MJ; Beerepoot LV; Groenewegen G; Lolkema MP; Tascilar M; Portielje JEA; Peters FPJ; Klümpen HJ; van der Noort V; Haanen JBAG; Voest EE;
JAMA Oncol; 2017 Apr; 3(4):501-508. PubMed ID: 27918762
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.
Jones RJ; Hussain SA; Protheroe AS; Birtle A; Chakraborti P; Huddart RA; Jagdev S; Bahl A; Stockdale A; Sundar S; Crabb SJ; Dixon-Hughes J; Alexander L; Morris A; Kelly C; Stobo J; Paul J; Powles T
J Clin Oncol; 2017 Jun; 35(16):1770-1777. PubMed ID: 28402747
[TBL] [Abstract][Full Text] [Related]
16. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.
Nishida Y; Urakawa H; Nakayama R; Kobayashi E; Ozaki T; Ae K; Matsumoto Y; Tsuchiya H; Goto T; Hiraga H; Naka N; Takahashi S; Ando Y; Ando M; Kuwatsuka Y; Hamada S; Ueda T; Kawai A
Int J Cancer; 2021 Jan; 148(1):140-149. PubMed ID: 32638374
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
Sharma A; Singh M; Chauhan R; Malik PS; Khurana S; Mathur S; Kumar S; Sreenivas V; Kumar L
Gynecol Oncol; 2021 Aug; 162(2):382-388. PubMed ID: 34088513
[TBL] [Abstract][Full Text] [Related]
19. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y
Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer.
Lin YS; Zhang X; Wang C; Liu YQ; Guan WM; Liang J
J Clin Endocrinol Metab; 2021 Jul; 106(8):e3027-e3036. PubMed ID: 33769497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
